Key statistics
On Friday, Jazz Pharmaceuticals PLC (JAZZ:NSQ) closed at 110.76, 11.81% above the 52 week low of 99.06 set on Jul 10, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 110.81 |
---|---|
High | 111.45 |
Low | 109.43 |
Bid | 106.00 |
Offer | 120.60 |
Previous close | 111.29 |
Average volume | 735.31k |
---|---|
Shares outstanding | 61.75m |
Free float | 59.97m |
P/E (TTM) | 19.02 |
Market cap | 6.84bn USD |
EPS (TTM) | 5.82 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
- Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
- Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
- Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
- Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
- Jazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies
- Jazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
- Jazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
- Jazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting
- Jazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
More ▼